Novel Pharmacological Approaches for Tourette Syndrome
- PDF / 259,744 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 1 Downloads / 168 Views
TOURETTE’S SYNDROME (E RICKETTS AND M YADEGAR, SECTION EDITORS)
Novel Pharmacological Approaches for Tourette Syndrome Julian Fletcher 1 & Davide Martino 1 & Tamara Pringsheim 1,2 Accepted: 10 September 2020 # Springer Nature Switzerland AG 2020
Abstract Purpose of the Review The need to develop novel pharmacological approaches for TS is balanced by the necessity for interventions to be safe and tolerable. This review provides an overview of studies of medications for TS over the last 3 years. Recent Findings Four studies of deutetrabenazine and valbenazine in TS failed in their primary outcomes. Ecopipam was more effective than placebo in reducing tics in children. Preliminary evidence suggests that a new endocannabinoid modulator (ABX1431) has an acute effect on tics in adults. Intravenous valproic acid was more effective than oral aripiprazole in children with severe tics. Taurine added to tiapride was superior to placebo added to tiapride in decreasing tics in children. The clonidine patch and vitamin D decreased tics in children compared with baseline assessment. Behavioral therapy was as effective as pharmacotherapy in decreasing tics in children. Summary There is emerging evidence for new treatments for tics, but more methodologically rigorous studies are needed to inform practice recommendations. Keywords Tourette syndrome . Tics . Pharmacotherapy
Introduction Tourette syndrome (TS) is a neuropsychiatric condition defined by the presence of motor and phonic tics. Tic onset typically occurs at an average age of 6 years old and follows a waxing and waning course over time, with many youth experiencing symptomatic improvement in late adolescence [1, 2]. TS is commonly associated with other psychiatric conditions including attention deficit hyperactivity disorder, obsessive compulsive disorder, and anxiety disorders. Tics impact and hinder the lives of children and their families, often significantly, and contribute to social, emotional, and behavioral problems. In 2019, the American Academy of Neurology (AAN) performed a systematic review on the treatment of Tourette syndrome and chronic tic disorders [3••] and an accompanying practice guideline with recommendations for treatment [4••]. This article is part of the Topical Collection on Tourette’s Syndrome * Tamara Pringsheim [email protected] 1
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada
2
Mathison Centre for Mental Health Research & Education, 3280 Hospital Drive NW, Calgary, Canada
The systematic review summarized the evidence on the efficacy of interventions for tics and the risks associated with their use. The practice guideline made recommendations based on the findings of the systematic review. In concluding that many interventions had only been studied in one randomized control trial of short duration, the systematic review underlined the need for novel pharmacological approaches for TS and comorbidities. While a number of pharmacotherapies demonstrated beneficial effects on tics, th
Data Loading...
